{"title":"First In Human Rapid Removal of Circulating Tumor Cells in Solid Metastatic Neoplasia By Microbind Affinity Blood Filter.","authors":"Sanja Ilic, Vedran Premuzic","doi":"10.1159/000542325","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We conducted a first-in-human trial evaluating safety and the potential for combined pathogen and CTC removal in patients with solid metastatic cancers.</p><p><strong>Methods: </strong>The Seraph procedure was performed at a hemodialysis clinic on ten consecutive patients with metastatic cancer whose liquid biopsy was positive for the epithelial cell adhesion molecule (EpCAM). All of the patients exerted positive bacterial or fungal isolates.</p><p><strong>Results: </strong>We have demonstrated the ability of Seraph100® Filter to remove both pathogens and circulating tumor cells, with median reduction of 71% within the 120 min, from patient blood.</p><p><strong>Discussion: </strong>High yield CTCs clearance could potentially benefit patients in diagnostic and personalized treatment of cancer to be elucidated in further research.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Purification","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542325","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: We conducted a first-in-human trial evaluating safety and the potential for combined pathogen and CTC removal in patients with solid metastatic cancers.
Methods: The Seraph procedure was performed at a hemodialysis clinic on ten consecutive patients with metastatic cancer whose liquid biopsy was positive for the epithelial cell adhesion molecule (EpCAM). All of the patients exerted positive bacterial or fungal isolates.
Results: We have demonstrated the ability of Seraph100® Filter to remove both pathogens and circulating tumor cells, with median reduction of 71% within the 120 min, from patient blood.
Discussion: High yield CTCs clearance could potentially benefit patients in diagnostic and personalized treatment of cancer to be elucidated in further research.
期刊介绍：
Practical information on hemodialysis, hemofiltration, peritoneal dialysis and apheresis is featured in this journal. Recognizing the critical importance of equipment and procedures, particular emphasis has been placed on reports, drawn from a wide range of fields, describing technical advances and improvements in methodology. Papers reflect the search for cost-effective solutions which increase not only patient survival but also patient comfort and disease improvement through prevention or correction of undesirable effects. Advances in vascular access and blood anticoagulation, problems associated with exposure of blood to foreign surfaces and acute-care nephrology, including continuous therapies, also receive attention. Nephrologists, internists, intensivists and hospital staff involved in dialysis, apheresis and immunoadsorption for acute and chronic solid organ failure will find this journal useful and informative. ''Blood Purification'' also serves as a platform for multidisciplinary experiences involving nephrologists, cardiologists and critical care physicians in order to expand the level of interaction between different disciplines and specialities.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
